30 May 2017 07:00
ARIX BIOSCIENCE PLC
Director/PDMR Shareholding
LONDON, 30 May 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or "the Company"), a global healthcare and life science company supporting medical innovation, announces that awards of shares have been made to several key members of its leadership team under the Company's Long Term Incentive Plan ("LTIP").
Awards of nil cost options have been made to Joseph Anderson, Chief Executive Officer, and James Rawlingson, Chief Financial Officer; a conditional share award has been made to Jonathan Peacock, Chairman.
These will be exercisable in three years' time, subject to the rules of the LTIP and to performance conditions relating to the growth of the Company's share price. Details of the maximum awards possible are set out below in the PDMR Dealing Notification Forms.
PDMR Dealing Notifications
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
PDMR DEALING NOTIFICATION | |||
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them | |||
1 | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Joseph Anderson | |
2 | Reason for the notification | ||
a) | Position / status | Chief Executive Officer | |
b) | Initial notification / Amendment | Initial Notification | |
3 | Details of issuer | ||
a) | Name | Arix Bioscience plc | |
b) | LEI | 213800OVT3AHQCXNIX43 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument | Ordinary Shares of Arix Bioscience plc | |
Identification code | GB00BD045071 | ||
b) | Nature of the transaction | Award of nil-cost options under the Arix Bioscience plc Long-term Incentive Plan ("LTIP") | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
Nil | 569,619 | ||
d) | Aggregated information | Aggregated price | Aggregated volume |
N/A | N/A | ||
e) | Date of the transaction | 26 May 2017 | |
f) | Place of the transaction | Outside of a trading venue | |
PDMR DEALING NOTIFICATION | |||
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them | |||
1 | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Jonathan Peacock | |
2 | Reason for the notification | ||
a) | Position / status | Chairman | |
b) | Initial notification / Amendment | Initial Notification | |
3 | Details of issuer | ||
a) | Name | Arix Bioscience plc | |
b) | LEI | 213800OVT3AHQCXNIX43 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument | Ordinary Shares of Arix Bioscience plc | |
Identification code | GB00BD045071 | ||
b) | Nature of the transaction | Conditional share award under the Arix Bioscience plc Long-term Incentive Plan ("LTIP") | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
Nil | 379,746 | ||
d) | Aggregated information | Aggregated price | Aggregated volume |
N/A | N/A | ||
e) | Date of the transaction | 26 May 2017 | |
f) | Place of the transaction | Outside of a trading venue | |
PDMR DEALING NOTIFICATION | |||
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them | |||
1 | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | James Hedley Rawlingson | |
2 | Reason for the notification | ||
a) | Position / status | Chief Financial Officer | |
b) | Initial notification / Amendment | Initial Notification | |
3 | Details of issuer | ||
a) | Name | Arix Bioscience plc | |
b) | LEI | 213800OVT3AHQCXNIX43 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument | Ordinary Shares of Arix Bioscience plc | |
Identification code | GB00BD045071 | ||
b) | Nature of the transaction | Award of nil-cost options under the Arix Bioscience plc Long-term Incentive Plan ("LTIP") | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
Nil | 205,062 | ||
d) | Aggregated information | Aggregated price | Aggregated volume |
N/A | N/A | ||
e) | Date of the transaction | 26 May 2017 | |
f) | Place of the transaction | Outside of a trading venue | |
For further information:
James Rawlingson Chief Financial Officer +44 (0)207 290 1050
- Ends -